Home › Funds › Octagon Capital Advisors LP › TRVI
Octagon Capital Advisors LP position in TRVI
TREVI THERAPEUTICS INC · Health Care
Octagon Capital Advisors LP reported holding 315,000 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.5M, representing 0.60% of its reported portfolio and ranking #22 among its reported holdings. Octagon Capital Advisors LP has disclosed TRVI holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's TRVI position evolved
Octagon Capital Advisors LP first disclosed a stake in TRVI in Q1 2025 at 3,322,000 shares (US$20.9M). The position peaked in Q4 2025 at 2,815,000 shares, worth US$35.2M. Across 7 filings, Octagon Capital Advisors LP increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 315,000 shares valued at US$4.5M. Notable position changes include a 47% trim in Q1 2026 (shares rose 56% over the following quarter), a 79% trim in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 3.32M | $20.90M | New |
| Q2 2025 | 3.67M | $20.09M | Add |
| Q3 2025 | 2.81M | $25.76M | Reduce |
| Q4 2025 | 2.81M | $35.24M | Hold |
| Q1 2026 | 1.49M | $17.72M | Reduce |
| Q2 2026 | 315.00K | $5.87M | Reduce |
| Q3 2026 | 315.00K | $4.51M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$189.3M), Frazier Life Sciences Management, L.P. (US$136.6M), Vivo Capital, LLC (US$60.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $189.34M · Q3 2026
- Frazier Life Sciences Management, L.P. 9.54M sh · $136.60M · Q3 2026
- Vivo Capital, LLC 4.23M sh · $60.57M · Q3 2026
- MPM BioImpact LLC 2.98M sh · $42.66M · Q3 2026
- Soleus Capital Management, L.P. 2.73M sh · $39.06M · Q3 2026
- First Light Asset Management, LLC 2.39M sh · $34.19M · Q3 2026
- Artia Global Partners LP 2.21M sh · $31.66M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $30.71M · Q3 2026
- Affinity Asset Advisors, LLC 1.80M sh · $25.78M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $24.96M · Q3 2026
- Saturn V Capital Management LP 1.57M sh · $22.54M · Q3 2026
- Siren, L.L.C. 1.52M sh · $21.82M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held TRVI?
Octagon Capital Advisors LP has disclosed TRVI holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Octagon Capital Advisors LP's current position in TRVI?
As of Q3 2026, Octagon Capital Advisors LP holds 315.00K shares of TRVI (TREVI THERAPEUTICS INC), valued at $4.51M, representing 0.60% of its reported portfolio and ranking #22.
Has Octagon Capital Advisors LP been buying or selling TRVI?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in TRVI. The position peaked in Q4 2025 at 2.81M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.